A Case Study with the Cytegrity™ Producer Cell Line in the scale-X™ Fixed-Bed Bioreactor
Join our insightful webinar to explore revolutionary advancements in Lentiviral Vector (LVV) production. With the industry facing challenges like batch-to-batch variability and high cGMP process costs, Genezen introduces a transformative approach with the Cytegrity™ Producer Cell Line (PCL) system in combination with Univercells Technologies’ scale-X™ fixed-bed bioreactor. This strategy addresses efficiency, scalability, and cost, significantly reducing the GMP footprint.
Key Highlights:
- Explore the current manufacturing obstacles and their impact on Cell and Gene Therapy (CGT) product accessibility.
- Discover how Cytegrity™ and scale-X™ integration surmounts traditional barriers, improving LV stability and enabling substantial manufacturing scale-up.
- See how this approach not only achieves high titers and cost efficiencies but also streamlines downstream processing, creating highly potent super lots.
- Understand the significant leap forward made by eliminating the need for cGMP-grade plasmids, enhancing scalability, reducing GMP space, and ensuring consistent yields.
Tailored for gene therapy development and manufacturing professionals, this webinar offers a deep dive into cutting-edge production methods that hold the promise of making therapies more scalable, efficient, and affordable. Engage directly with industry leaders to explore how these innovations can revolutionize your projects and the CGT field at large.
